Skip to main content
. Author manuscript; available in PMC: 2023 Jun 15.
Published in final edited form as: Clin Cancer Res. 2022 Dec 15;28(24):5238–5240. doi: 10.1158/1078-0432.CCR-22-1779

Figure 1:

Figure 1:

Transforming growth factor-β (TGFβ) signaling in tumor cells drives epithelial to mesenchymal cellular transformation, promotes increased angiogenesis, and recruits immunosuppressive populations such as regulatory T cells. By simultaneously targeting PD-L1 expression and TGF-β within the tumor microenvironment, SHR-1701 creates a more favorable pro-inflammatory milieu.